Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

• Status: Not yet recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BioAtla, Inc.

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma

• Age ≥ 18 years

• Adequate renal function

• Adequate liver function

• Adequate hematological function

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

• Patients must not have clinically significant cardiac disease.

• Patients must not have known non-controlled CNS metastasis.

• Patients must not have active autoimmune disease or a documented history of autoimmune disease.

• Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.

• Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.

• Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.

• Patients must not be women who are pregnant or breast feeding.